Latest Insider Transactions at Cerus Corp (CERS)
This section provides a real-time view of insider transactions for Cerus Corp (CERS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of CERUS CORP to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of CERUS CORP's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 16
2024
|
Chrystal Menard Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
16,667
-3.51%
|
$16,667
$1.71 P/Share
|
|
Dec 12
2024
|
Eric Bjerkholt |
SELL
Open market or private sale
|
Direct |
20,000
-10.98%
|
$20,000
$1.78 P/Share
|
|
Sep 04
2024
|
Kevin Dennis Green Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
54,272
-9.19%
|
$108,544
$2.15 P/Share
|
|
Sep 03
2024
|
Kevin Dennis Green Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
28,385
-4.59%
|
$56,770
$2.18 P/Share
|
|
Aug 15
2024
|
Chrystal Menard Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
16,667
-3.4%
|
$33,334
$2.06 P/Share
|
|
Aug 02
2024
|
Richard J Benjamin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
21,605
-4.7%
|
$43,210
$2.5 P/Share
|
|
Jul 01
2024
|
Dean A. Gregory |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+50.0%
|
-
|
|
Jun 05
2024
|
Gail Schulze Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+19.66%
|
$200,000
$5.0 P/Share
|
|
Jun 05
2024
|
Hua Shan Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+35.59%
|
$200,000
$5.0 P/Share
|
|
Jun 05
2024
|
Daniel N Swisher Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+21.39%
|
$200,000
$5.0 P/Share
|
|
Jun 05
2024
|
Frank Witney Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+15.38%
|
$200,000
$5.0 P/Share
|
|
Jun 05
2024
|
Ann Lucena Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+26.27%
|
$200,000
$5.0 P/Share
|
|
Jun 05
2024
|
Timothy L. Moore Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+21.61%
|
$200,000
$5.0 P/Share
|
|
Jun 05
2024
|
Jami K Nachtsheim Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+21.24%
|
$200,000
$5.0 P/Share
|
|
Jun 05
2024
|
Eric Bjerkholt |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+18.01%
|
$200,000
$5.0 P/Share
|
|
May 13
2024
|
Hua Shan Director |
BUY
Open market or private purchase
|
Direct |
2,500
+7.17%
|
$2,500
$1.99 P/Share
|
|
May 10
2024
|
Jami K Nachtsheim Director |
BUY
Open market or private purchase
|
Direct |
2,000
+1.81%
|
$2,000
$1.79 P/Share
|
|
May 09
2024
|
Frank Witney Director |
BUY
Open market or private purchase
|
Direct |
20,000
+10.0%
|
$20,000
$1.89 P/Share
|
|
May 09
2024
|
Daniel N Swisher Jr Director |
BUY
Open market or private purchase
|
Direct |
2,500
+2.28%
|
$2,500
$1.88 P/Share
|
|
Mar 14
2024
|
Kevin Dennis Green Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
21,497
-3.36%
|
$21,497
$1.97 P/Share
|
|
Mar 14
2024
|
Chrystal Menard Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
17,824
-3.5%
|
$17,824
$1.97 P/Share
|
|
Mar 14
2024
|
William Mariner Greenman President and CEO |
SELL
Open market or private sale
|
Direct |
63,611
-1.96%
|
$127,222
$2.02 P/Share
|
|
Mar 14
2024
|
Vivek K Jayaraman Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
26,794
-2.96%
|
$26,794
$1.97 P/Share
|
|
Mar 14
2024
|
Laurence M Corash Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
14,360
-0.61%
|
$14,360
$1.97 P/Share
|
|
Mar 14
2024
|
Richard J Benjamin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
17,738
-3.72%
|
$17,738
$1.97 P/Share
|
|
Mar 13
2024
|
Kevin Dennis Green Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
21,058
-3.18%
|
$42,116
$2.02 P/Share
|
|
Mar 13
2024
|
Chrystal Menard Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
17,460
-3.32%
|
$34,920
$2.06 P/Share
|
|
Mar 13
2024
|
Carol Moore SVP Reg. & Quality |
SELL
Open market or private sale
|
Direct |
20,619
-2.04%
|
$41,238
$2.02 P/Share
|
|
Mar 13
2024
|
William Mariner Greenman President and CEO |
SELL
Open market or private sale
|
Direct |
62,315
-1.88%
|
$124,630
$2.06 P/Share
|
|
Mar 13
2024
|
Vivek K Jayaraman Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
26,247
-2.82%
|
$52,494
$2.06 P/Share
|
|
Mar 13
2024
|
Laurence M Corash Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
14,067
-0.59%
|
$28,134
$2.06 P/Share
|
|
Mar 13
2024
|
Richard J Benjamin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
17,377
-3.51%
|
$34,754
$2.06 P/Share
|
|
Mar 12
2024
|
Kevin Dennis Green Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,666
+3.17%
|
-
|
|
Mar 12
2024
|
Chrystal Menard Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,666
+3.07%
|
-
|
|
Mar 12
2024
|
Carol Moore SVP Reg. & Quality |
BUY
Exercise of conversion of derivative security
|
Direct |
11,666
+2.23%
|
-
|
|
Mar 12
2024
|
William Mariner Greenman President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
64,666
+1.92%
|
-
|
|
Mar 12
2024
|
Vivek K Jayaraman Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+2.61%
|
-
|
|
Mar 12
2024
|
Laurence M Corash Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,666
+0.7%
|
-
|
|
Mar 12
2024
|
Richard J Benjamin Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,666
+3.26%
|
-
|
|
Mar 08
2024
|
Richard J Benjamin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
29,378
-5.79%
|
$58,756
$2.4 P/Share
|
|
Mar 01
2024
|
Vivek K Jayaraman Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
240,000
+20.93%
|
-
|
|
Mar 01
2024
|
Chrystal Menard Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
160,000
+23.9%
|
-
|
|
Mar 01
2024
|
Carol Moore SVP Reg. & Quality |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+13.05%
|
-
|
|
Mar 01
2024
|
Laurence M Corash Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+3.69%
|
-
|
|
Mar 01
2024
|
Kevin Dennis Green Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+23.82%
|
-
|
|
Mar 01
2024
|
William Mariner Greenman President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
575,000
+15.06%
|
-
|
|
Mar 01
2024
|
Richard J Benjamin Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
160,000
+23.97%
|
-
|
|
Dec 13
2023
|
Eric Bjerkholt |
BUY
Open market or private purchase
|
Direct |
10,000
+6.57%
|
$10,000
$1.62 P/Share
|
|
Aug 22
2023
|
Ann Lucena Director |
BUY
Open market or private purchase
|
Direct |
7,500
+9.4%
|
$7,500
$1.68 P/Share
|
|
Aug 21
2023
|
Eric Bjerkholt |
BUY
Open market or private purchase
|
Direct |
10,000
+7.04%
|
$10,000
$1.72 P/Share
|